Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F. Singer, Michael Gnant, Margaretha Rudas et al.|Clinical Cancer Research|2017Cited by 61
Molecular profiling in breast cancer—ready for clinical routine?Kristina A. Tendl, Zsuzsanna Bagó-Horváth|memo - Magazine of European Medical Oncology|2020Cited by 12
Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of ViennaKristina A. Tendl, Zsuzsanna Bagó-Horváth, Leonhard Müllauer et al.|Annals of Oncology|2019Cited by 1